Health Economics›Acute myeloid leukemia›Maintenance after upfront therapy including allogeneic HSCT

Maintenance after upfront therapy including allogeneic HSCT

Acute myeloid leukemia · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Midostaurin monotherapy Variant #01	FLT3	R 76 418	28d	—	—	—	—	—
Sorafenib monotherapy Variant #04	FLT3	R 37 339	28d	—	—	—	—	1
Observation Partial	FLT3	—	—	—	14.8 mo	—	—	—
Placebo Partial	FLT3	—	—	~4.2 mo	~8.0 mo	—	—	145
Quizartinib monotherapy Variant #01 Partial	FLT3	—	28d	—	~6.2 mo	—	—	1

5 of 5 regimens shown